These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 33267874)

  • 1. Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells.
    Ghaleb A; Padellan M; Marchenko N
    Breast Cancer Res; 2020 Dec; 22(1):133. PubMed ID: 33267874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irradiation induces p53 loss of heterozygosity in breast cancer expressing mutant p53.
    Ghaleb A; Yallowitz A; Marchenko N
    Commun Biol; 2019; 2():436. PubMed ID: 31799437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of HSF1 activity by wildtype p53 creates a driving force for p53 loss-of-heterozygosity.
    Isermann T; Şener ÖÇ; Stender A; Klemke L; Winkler N; Neesse A; Li J; Wegwitz F; Moll UM; Schulz-Heddergott R
    Nat Commun; 2021 Jun; 12(1):4019. PubMed ID: 34188043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The onset of p53 loss of heterozygosity is differentially induced in various stem cell types and may involve the loss of either allele.
    Shetzer Y; Kagan S; Koifman G; Sarig R; Kogan-Sakin I; Charni M; Kaufman T; Zapatka M; Molchadsky A; Rivlin N; Dinowitz N; Levin S; Landan G; Goldstein I; Goldfinger N; Pe'er D; Radlwimmer B; Lichter P; Rotter V; Aloni-Grinstein R
    Cell Death Differ; 2014 Sep; 21(9):1419-31. PubMed ID: 24832469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo.
    Alexandrova EM; Mirza SA; Xu S; Schulz-Heddergott R; Marchenko ND; Moll UM
    Cell Death Dis; 2017 Mar; 8(3):e2661. PubMed ID: 28277540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Nek2 centrosome-mitotic kinase contributes to the mesenchymal state, cell invasion, and migration of triple-negative breast cancer cells.
    Rivera-Rivera Y; Marina M; Jusino S; Lee M; Velázquez JV; Chardón-Colón C; Vargas G; Padmanabhan J; Chellappan SP; Saavedra HI
    Sci Rep; 2021 Apr; 11(1):9016. PubMed ID: 33907253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.
    Iyer SV; Parrales A; Begani P; Narkar A; Adhikari AS; Martinez LA; Iwakuma T
    Oncotarget; 2016 Feb; 7(5):5401-15. PubMed ID: 26700961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gain-of-function mutant p53 in cancer progression and therapy.
    Zhang C; Liu J; Xu D; Zhang T; Hu W; Feng Z
    J Mol Cell Biol; 2020 Sep; 12(9):674-687. PubMed ID: 32722796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic Aberrations and Interaction of NEK2 and TP53 Accelerate Aggressiveness of Multiple Myeloma.
    Feng X; Guo J; An G; Wu Y; Liu Z; Meng B; He N; Zhao X; Chen S; Zhu Y; Xia J; Li X; Yu Z; Li R; Ren G; Chen J; Wu M; He Y; Qiu L; Zhou J; Zhou W
    Adv Sci (Weinh); 2022 Mar; 9(9):e2104491. PubMed ID: 35088582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitotic perturbations induced by Nek2 overexpression require interaction with TRF1 in breast cancer cells.
    Lee J; Gollahon L
    Cell Cycle; 2013 Dec; 12(23):3599-614. PubMed ID: 24091727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic interactions between Brca1 and Gadd45a in centrosome duplication, genetic stability, and neural tube closure.
    Wang X; Wang RH; Li W; Xu X; Hollander MC; Fornace AJ; Deng CX
    J Biol Chem; 2004 Jul; 279(28):29606-14. PubMed ID: 15123655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion.
    Schulz-Heddergott R; Stark N; Edmunds SJ; Li J; Conradi LC; Bohnenberger H; Ceteci F; Greten FR; Dobbelstein M; Moll UM
    Cancer Cell; 2018 Aug; 34(2):298-314.e7. PubMed ID: 30107178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. E2F activators signal and maintain centrosome amplification in breast cancer cells.
    Lee MY; Moreno CS; Saavedra HI
    Mol Cell Biol; 2014 Jul; 34(14):2581-99. PubMed ID: 24797070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gain of function mutant p53 protein activates AKT through the Rac1 signaling to promote tumorigenesis.
    Yue X; Wu F; Li Y; Liu J; Boateng M; Mandava K; Zhang C; Feng Z; Gao J; Hu W
    Cell Cycle; 2020 Jun; 19(11):1338-1351. PubMed ID: 32275841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ErbB2 inhibition by lapatinib promotes degradation of mutant p53 protein in cancer cells.
    Li D; Marchenko ND
    Oncotarget; 2017 Jan; 8(4):5823-5833. PubMed ID: 27791982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancerous inhibitor of protein phosphatase 2A (CIP2A) protein is involved in centrosome separation through the regulation of NIMA (never in mitosis gene A)-related kinase 2 (NEK2) protein activity.
    Jeong AL; Lee S; Park JS; Han S; Jang CY; Lim JS; Lee MS; Yang Y
    J Biol Chem; 2014 Jan; 289(1):28-40. PubMed ID: 24214971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant p53 Amplifies Epidermal Growth Factor Receptor Family Signaling to Promote Mammary Tumorigenesis.
    Yallowitz AR; Li D; Lobko A; Mott D; Nemajerova A; Marchenko N
    Mol Cancer Res; 2015 Apr; 13(4):743-54. PubMed ID: 25573952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ubiquitin ligase TRIM21 regulates mutant p53 accumulation and gain of function in cancer.
    Liu J; Zhang C; Xu D; Zhang T; Chang CY; Wang J; Liu J; Zhang L; Haffty BG; Zong WX; Hu W; Feng Z
    J Clin Invest; 2023 Mar; 133(6):. PubMed ID: 36749630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LIN9 and NEK2 Are Core Regulators of Mitotic Fidelity That Can Be Therapeutically Targeted to Overcome Taxane Resistance.
    Roberts MS; Sahni JM; Schrock MS; Piemonte KM; Weber-Bonk KL; Seachrist DD; Avril S; Anstine LJ; Singh S; Sizemore ST; Varadan V; Summers MK; Keri RA
    Cancer Res; 2020 Apr; 80(8):1693-1706. PubMed ID: 32054769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silencing of E2F3 suppresses tumor growth of Her2+ breast cancer cells by restricting mitosis.
    Lee M; Oprea-Ilies G; Saavedra HI
    Oncotarget; 2015 Nov; 6(35):37316-34. PubMed ID: 26512919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.